Anteris Technologies (ASX:AVR) ROCE % : -523.18% (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Anteris Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anteris Technologies's annualized ROCE % for the quarter that ended in Jun. 2024 was -523.18%.

Anteris Technologies ROCE % Historical Data

The historical data trend for Anteris Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies ROCE % Chart

Anteris Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-28.77

-126.75

-202.00

-267.42

-288.28

Anteris Technologies Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-169.25	-176.03	-291.90	-270.17	-523.18

Anteris Technologies ROCE % Calculation

Anteris Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-68.918	/	( ( (23.479 - 7.541)	+	(45.701 - 13.825) )	/ 2 )
	=	-68.918	/	( (15.938	+	31.876)	/ 2 )
	=	-68.918	/	23.907
	=	-288.28 %

Anteris Technologies's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-106.446	/	( ( (45.701 - 13.825)	+	(26.531 - 17.715) )	/ 2 )
	=	-106.446	/	( ( 31.876	+	8.816 )	/ 2 )
	=	-106.446	/	20.346
	=	-523.18 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Anteris Technologies (ASX:AVR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anteris Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (ASX:AVR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AMEUF:USA

Address

9 Sherwood Road, Level 3, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066

Website

https://www.anteristech.com

Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. It is also engaged in research and development of ComASUR, a delivery system that allows accurate valve placement, and the manufacturing and selling of proprietary ADAPT regenerative tissue products. The company generates a majority of its revenue from the United States and the rest from Switzerland and Australia.

Anteris Technologies Headlines

From GuruFocus

Anteris Technologies (AVR) Plans $100 Million IPO on Nasdaq

By GuruFocus News • 12-10-2024